An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

Key Inclusion Criteria:

• Must have moderate to severe chronic TED with documented evidence of ocular symptomsor signs that began greater than 15 months prior to screening

• Must have had a clinical diagnosis of TED, with any CAS (0-7)

• Must agree to use highly effective contraception as specified in the protocol

• Female TED participants must have a negative serum pregnancy test at screening

Key Exclusion Criteria:

• Must not have received prior treatment with another anti-IGF-1R therapy

• Must not have received systemic corticosteroids for any condition, including TED, orselenium within 2 weeks prior to first dose

• Must not have received other immunosuppressive drugs or another investigationalagent for any condition, including TED, or any other therapy for TED, within 8 weeksprior to first dose

• Must not have received radioactive iodine (RAI) treatment within 8 weeks prior tofirst dose

• Must not have a pre-existing ophthalmic condition in the study eye that in theopinion of the study doctor would confound interpretation of the study results

• Must not have had previous orbital irradiation or decompression surgery for TED tothe study eye's orbit

• Must not have inflammatory bowel disease

• Have abnormal baseline audiometry Pure Tone Average (PTA) assessment or history ofsignificant (as determined by the Investigator) ear pathology, relevant ear surgeryor hearing loss.

• Female TED participants must not be pregnant or lactating